Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Net Margin of 136.03% for Q1 2026, down 2740.0% year-over-year from 5.15% in Q1 2025, and down 119.33% quarter-over-quarter from 62.02% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Net Margin (2016 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 11 years of Net Margin data on file, last reported at 136.03% in Q1 2026.
- Net Margin for Q1 2026 came in at 136.03%, down 2740.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 90.92% (down 9307.0% YoY), and the FY2025 annual result was 85.44%, down 8419.0% from the prior year.
- Net Margin retreated to 136.03% in Q1 2026 per RARE's latest filing, from 62.02% in the prior quarter.
- Over five years, Net Margin peaked at 260.43% in Q4 2024 and troughed at 270.23% in Q3 2022.
- A 5-year average of 113.36% and a median of 136.03% in 2026 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin soared 35761 bps in 2024, then slumped 32246 bps in 2025.
- A 5-year view of Net Margin shows it stood at 148.5% in 2022, then jumped by 35 bps to 97.17% in 2023, then jumped by 368 bps to 260.43% in 2024, then slumped by 124 bps to 62.02% in 2025, then sank by 119 bps to 136.03% in 2026.
- Business Quant data shows RARE's Net Margin at 136.03% in Q1 2026, 62.02% in Q4 2025, and 112.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -136.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -136.03% |
| Dec 31, 2025 | -62.02% |
| Sep 30, 2025 | -112.81% |
| Jun 30, 2025 | -69.04% |
| Mar 31, 2025 | -108.63% |
| Dec 31, 2024 | 260.43% |
| Sep 30, 2024 | -95.71% |
| Jun 30, 2024 | -89.51% |
| Mar 31, 2024 | -156.83% |
| Dec 31, 2023 | -97.17% |
| Sep 30, 2023 | -162.82% |
| Jun 30, 2023 | -147.57% |
| Mar 31, 2023 | -163.16% |
| Dec 31, 2022 | -148.50% |
| Sep 30, 2022 | -270.23% |
| Jun 30, 2022 | -177.03% |
| Mar 31, 2022 | -190.55% |
| Dec 31, 2021 | -149.65% |
| Sep 30, 2021 | -89.41% |
| Jun 30, 2021 | -140.76% |